Composant-7 du complexe de maintenance des minichromosomes : Questions médicales fréquentes
Nom anglais: Minichromosome Maintenance Complex Component 7
Descriptor UI:D064168
Tree Number:D12.776.664.235.750.700
Termes MeSH sélectionnés :
Complement Activation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Composant-7 du complexe de maintenance des minichromosomes : Questions médicales les plus fréquentes",
"headline": "Composant-7 du complexe de maintenance des minichromosomes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Composant-7 du complexe de maintenance des minichromosomes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-23",
"dateModified": "2025-04-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Composant-7 du complexe de maintenance des minichromosomes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de maintenance des minichromosomes",
"url": "https://questionsmedicales.fr/mesh/D064110",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de maintenance des minichromosomes",
"code": {
"@type": "MedicalCode",
"code": "D064110",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.235.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Composant-7 du complexe de maintenance des minichromosomes",
"alternateName": "Minichromosome Maintenance Complex Component 7",
"code": {
"@type": "MedicalCode",
"code": "D064168",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Qing Yang",
"url": "https://questionsmedicales.fr/author/Qing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China."
}
},
{
"@type": "Person",
"name": "Binhui Xie",
"url": "https://questionsmedicales.fr/author/Binhui%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatobiliary Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China."
}
},
{
"@type": "Person",
"name": "Hui Tang",
"url": "https://questionsmedicales.fr/author/Hui%20Tang",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China."
}
},
{
"@type": "Person",
"name": "Wei Meng",
"url": "https://questionsmedicales.fr/author/Wei%20Meng",
"affiliation": {
"@type": "Organization",
"name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China."
}
},
{
"@type": "Person",
"name": "Changchang Jia",
"url": "https://questionsmedicales.fr/author/Changchang%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Cell-gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots.",
"datePublished": "2024-06-12",
"url": "https://questionsmedicales.fr/article/38933264",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2024.1368852"
}
},
{
"@type": "ScholarlyArticle",
"name": "Synthetic Oligodeoxynucleotide CpG Motifs Activate Human Complement through Their Backbone Structure and Induce Complement-Dependent Cytokine Release.",
"datePublished": "2022-09-14",
"url": "https://questionsmedicales.fr/article/36104112",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4049/jimmunol.2101191"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays.",
"datePublished": "2023-02-11",
"url": "https://questionsmedicales.fr/article/36816333",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/IJN.S384184"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling complement activation on human glomerular microvascular endothelial cells.",
"datePublished": "2023-10-25",
"url": "https://questionsmedicales.fr/article/37954621",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1206409"
}
},
{
"@type": "ScholarlyArticle",
"name": "Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.",
"datePublished": "2022-07-16",
"url": "https://questionsmedicales.fr/article/35853795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.smim.2022.101640"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Nucléoprotéines",
"item": "https://questionsmedicales.fr/mesh/D009698"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines chromosomiques nonhistones",
"item": "https://questionsmedicales.fr/mesh/D002868"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines de maintenance des minichromosomes",
"item": "https://questionsmedicales.fr/mesh/D064110"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composant-7 du complexe de maintenance des minichromosomes",
"item": "https://questionsmedicales.fr/mesh/D064168"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Composant-7 du complexe de maintenance des minichromosomes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Comment diagnostiquer une anomalie du Composant-7 ?\nQuels tests sont utilisés pour évaluer le Composant-7 ?\nY a-t-il des marqueurs spécifiques pour le Composant-7 ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels symptômes peuvent indiquer un problème avec le Composant-7 ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Complement+Activation&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quels sont les symptômes d'une défaillance du Composant-7 ?\nPeut-on observer des symptômes cliniques ?\nLes symptômes varient-ils selon les individus ?\nY a-t-il des signes précoces d'anomalies ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Complement+Activation&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Peut-on prévenir les anomalies du Composant-7 ?\nY a-t-il des facteurs environnementaux à éviter ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes vaccinations peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Complement+Activation&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quels traitements sont disponibles pour les anomalies du Composant-7 ?\nLa thérapie génique est-elle efficace ?\nDes médicaments spécifiques sont-ils utilisés ?\nLe traitement nécessite-t-il une surveillance régulière ?\nY a-t-il des effets secondaires aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Complement+Activation&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quelles complications peuvent survenir avec des anomalies du Composant-7 ?\nLes anomalies peuvent-elles affecter la fertilité ?\nY a-t-il des risques de maladies associées ?\nLes complications sont-elles réversibles ?\nComment les complications sont-elles traitées ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Complement+Activation&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Composant-7 du complexe de maintenance des minichromosomes",
"description": "Quels sont les facteurs de risque pour les anomalies du Composant-7 ?\nL'âge influence-t-il le risque d'anomalies ?\nLe mode de vie affecte-t-il le risque ?\nY a-t-il des antécédents familiaux à considérer ?\nLes infections pendant la grossesse sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Complement+Activation&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie du Composant-7 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le Composant-7 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de Western blot et les analyses de PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour le Composant-7 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs protéiques spécifiques peuvent indiquer des dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être nécessaire pour des analyses plus approfondies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le Composant-7 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la division cellulaire peuvent être des indicateurs."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une défaillance du Composant-7 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles de la division cellulaire et des anomalies chromosomiques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cliniques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes cliniques peuvent apparaître, mais ils sont souvent non spécifiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la gravité de l'anomalie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes précoces d'anomalies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes précoces peuvent inclure des retards de croissance cellulaire."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies du Composant-7 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les toxines et les radiations peut réduire les risques d'anomalies."
}
},
{
"@type": "Question",
"name": "Des dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers peuvent aider à détecter des anomalies précocement."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui affectent la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les anomalies du Composant-7 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments ciblés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique montre des résultats prometteurs dans certains cas."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques peuvent être utilisés pour cibler les anomalies."
}
},
{
"@type": "Question",
"name": "Le traitement nécessite-t-il une surveillance régulière ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière est essentielle pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, nécessitant une gestion attentive."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies du Composant-7 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers et des troubles génétiques."
}
},
{
"@type": "Question",
"name": "Les anomalies peuvent-elles affecter la fertilité ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent entraîner des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques accrus de maladies métaboliques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais pas toutes sont réversibles."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement des complications dépend de leur nature et de leur gravité."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies du Composant-7 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque d'anomalies chromosomiques."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain peut augmenter le risque d'anomalies génétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antécédents familiaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections pendant la grossesse sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections pendant la grossesse peuvent affecter le développement chromosomique."
}
}
]
}
]
}
The classical pathway of the complement system is activated by the binding of C1q in the C1 complex to the target activator, including immune complexes. Factor H is regarded as the key downregulatory ...
Bacterial and mitochondrial DNA, sharing an evolutionary origin, act as danger-associated molecular patterns in infectious and sterile inflammation. They both contain immunomodulatory CpG motifs. Inte...
The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune syst...
We treated commercially available pooled sera (PS) from healthy males, individual sera from healthy donors and from patients suffering from cancer, immunodeficiency and allergies with small molecules ...
The level of complement activation in PS differed significantly from responses of individual donors (p < 0.01). Only seven out of 32 investigated sera from healthy donors responded similarly to the po...
Our studies demonstrate that the use of pooled serum can lead to an over- or under-estimation of immunological response in particular for individuals with pre-existing pathologies. This is of high rel...
Atypical hemolytic uremic syndrome (aHUS) is a rare kidney disease caused by dysregulation of the complement alternative pathway. The complement dysregulation specifically leads to damage to the glome...
Endothelial cells were incubated with human test sera and stained with an anti-C5b-9 antibody to visualize and quantify complement depositions on the cells with immunofluorescence microscopy....
First, we showed that zymosan-activated sera resulted in increased endothelial C5b-9 depositions compared to normal human serum (NHS). The levels of C5b-9 depositions were similar between conditionall...
In conclusion, we demonstrate a robust and reliable model to adequately measure C5b-9-based complement deposition on human control and patient ciGMVECs. This model can be used to study the pathophysio...
Patients in the intensive care unit (ICU) often straddle the divide between life and death. Understanding the complex underlying pathomechanisms relevant to such situations may help intensivists selec...
The complement system which is part of the innate immune response against invading pathogens represents a powerful mechanism for killing of infected cells. Utilizing direct complement recruitment for ...
Cancer-related inflammation plays a central role in the establishment of tumor-promoting mechanisms. Tumor-associated myeloid cells, which engage in complex interactions with cancer cells, as well as ...
Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of...
Single donor apheresis platelet concentrates (SDA PCs) were produced in a regional setting of the French Blood Establishment. After transfusion samples were collected from PC and possible AR in patien...
A total of 56 PC were included in the study. 30 PC induced no AR, and 26 induced AR (Febrile non-hemolytic transfusion reaction n = 16; Atypical Allergic Transfusion Reactions n = 11; hemodynamic inst...
In this study, we observed an association between HMGB1 and CAP and the incidence of AR. Furthermore, we demonstrated that both HMGB1 and complement activation were correlated to platelet activation....
Anti-platelet factor 4 (PF4)/heparin immune complexes that cause heparin-induced thrombocytopenia (HIT) activate complement via the classical pathway. Previous studies have shown that the alternative ...
These studies sought to examine the contributions of the alternative pathway to complement activation by HIT antibodies....
Using IgG monoclonal (KKO) and/or patient-derived HIT antibodies, we compared the effects of classical pathway (BBK32 and C1-esterase inhibitor [C1-INH]), alternative pathway (anti-factor B [fB] or fa...
Classical pathway inhibitors BBK32 and C1-INH and the combined classical/alternative pathway inhibitor sCR1 prevented KKO/HIT immune complex-induced complement activation, including release of C3 and ...
Collectively, these findings suggest the alternative pathway contributes little in support of complement activation by HIT immune complexes. Additional in vitro and in vivo studies are required to exa...
Increasing evidence suggests that activation of the complement system plays a key role in the pathogenesis and disease severity of Coronavirus disease 2019 (COVID-19). We used a systematic approach to...